A Brookings, SD, based animal health company has reported (Feb. 25, 2025) successes in making H5N1 vaccines commercially available to animal owners and veterinarians.
Medgene has entered into a distribution agreement with Elanco Animal Health to accelerate the company’s support of the U.S. dairy industry, pending a final decision by the U.S. Department of Agriculture to vaccinate dairy cattle. Medgene’s H5N1 vaccine for dairy cattle has met all requirements of USDA’s platform technology guidelines and is in the final stages of review for conditional license approval. H5N1-infected dairies have experienced mortality, milk production loss with limited recovery, and abortion storms in pregnant heifers.
Medgene has previously worked with USDA’s Center for Veterinary Biologics to develop platform technology vaccines for emerging and foreign animal diseases, such as rabbit hemorrhagic disease, under specific regulatory guidelines for platform technologies.
As Medgene’s H5N1 vaccine for dairy cattle awaits USDA-CVB completion of departmental review, the company has made progress in essential testing for poultry and companion animal applications. USDA’s Agricultural Research Service is currently testing Medgene’s H5N1 vaccine in turkeys and egg-laying hens. Medgene has also recently completed its field safety study in turkeys.
Additionally, Medgene is collaborating with Cornell University to test its H5N1 vaccine in cats, which according to the American Veterinary Medical Association, have experienced mortality from consuming H5N1-infected products. Initial antibody titers from Medgene’s H5N1 vaccine in cats have surpassed the company’s expectations.
Comments